PUBLISHER: The Business Research Company | PRODUCT CODE: 1945238
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945238
A glucose biosensor is a specialized device designed for measuring glucose levels in different samples, commonly found in biological fluids such as blood or interstitial fluid. Widely applied in healthcare, especially for diabetes management, these biosensors facilitate convenient and frequent monitoring of blood glucose levels.
The primary product categories for glucose biosensors include continuous glucose monitoring, self-monitoring blood glucose, and non-invasive glucose monitoring. Continuous glucose monitoring (CGM) involves using a miniature sensor implanted under the skin to measure glucose levels in the patient's body. This method offers a more comprehensive view of glucose levels compared to standard fingerstick glucose monitoring and provides real-time results. The technologies predominantly used are electrochemical biosensors, optical biosensors, piezoelectric biosensors, and others. These biosensors find applications across various end-users such as hospitals, home care, diagnostic centers, clinics, and others.
Tariffs are influencing the glucose biosensors market by increasing costs of imported sensors, microelectronics, enzymes, test strips, and wearable components used in CGM and SMBG systems. Healthcare providers and device manufacturers in North America and Europe are most affected due to dependence on global semiconductor and biosensor supply chains, while Asia-Pacific faces higher production and export costs. These tariffs are raising device prices and slowing large-scale adoption. However, they are also encouraging domestic biosensor manufacturing, localized electronics assembly, and regional innovation in cost-optimized glucose monitoring solutions.
The glucose biosensors market research report is one of a series of new reports from The Business Research Company that provides glucose biosensors market statistics, including glucose biosensors industry global market size, regional shares, competitors with a glucose biosensors market share, detailed glucose biosensors market segments, market trends and opportunities, and any further data you may need to thrive in the glucose biosensors industry. This glucose biosensors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glucose biosensors market size has grown rapidly in recent years. It will grow from $16.72 billion in 2025 to $18.83 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increasing prevalence of diabetes, rising demand for home-based monitoring solutions, improvements in biosensor sensitivity, expansion of point-of-care diagnostics, growing patient awareness of glucose management.
The glucose biosensors market size is expected to see rapid growth in the next few years. It will grow to $30.88 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing adoption of digital diabetes management tools, rising demand for non-invasive monitoring, expansion of personalized healthcare solutions, growing investments in biosensor R&D, increasing use of AI-driven glucose analytics. Major trends in the forecast period include increasing adoption of continuous glucose monitoring systems, rising demand for wearable glucose biosensors, growing integration of mobile health platforms, expansion of non-invasive glucose monitoring technologies, enhanced focus on real-time data accuracy.
The increasing prevalence of diabetes is projected to drive the growth of the glucose biosensors market in the coming years. Diabetes is a chronic condition that occurs when the pancreas does not produce sufficient insulin or when the body is unable to effectively use the insulin produced. Patients with diabetes rely on glucose biosensors to regularly monitor their blood glucose levels, allowing them to manage their condition more effectively and adjust their medication as needed. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the growing prevalence of diabetes is a significant factor driving the expansion of the glucose biosensors market.
Major companies in the glucose biosensor market are focusing on developing advanced solutions, such as next-generation continuous glucose monitoring (CGM) sensors, to provide real-time, minute-by-minute glucose readings with optional alerts, enhancing diabetes management and patient safety. Next-generation CGM sensors continuously measure glucose levels in the interstitial fluid at frequent intervals, delivering real-time data, trend alerts, and optional alarms to help patients and clinicians manage diabetes more effectively. For example, in August 2025, Abbott Laboratories, a US-based healthcare company, launched the next-generation FreeStyle Libre 2 Plus sensor, which provides continuous glucose readings every minute directly to a compatible smartphone without the need for manual scanning. The sensor offers automatic real-time glucose monitoring with customizable alerts for high or low glucose levels. It is designed for comfort, wearable for up to 15 days, suitable for children aged 2 and above, and can sync with apps to share data with caregivers and healthcare professionals.
In May 2023, Medtronic plc, an Ireland-based medical device company, completed the acquisition of EOFLOW Co., Ltd. for $738 million. Through this strategic acquisition, Medtronic plc aims to broaden treatment options, cater to the demand for discreet delivery, and strengthen its position in the market. EOFLOW Co. Ltd. is a South Korea-based medical device company specialized in developing and manufacturing wearable drug delivery systems.
Major companies operating in the glucose biosensors market are Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Medtronic plc, Senseonics Holdings, GlySens Incorporated, LifeScan Inc., Ascensia Diabetes Care Holdings Inc., Nova Biomedical Corporation, AgaMatrix Inc., Trividia Health, Ypsomed AG, Universal Biosensors Inc., SD Biosensor Inc., Taidoc Technology Corporation, Nipro Corporation, i-SENS Inc., ACON Laboratories Inc., ARKRAY Inc., Menarini Diagnostics
North America was the largest region in the glucose biosensors market in 2025. The regions covered in the glucose biosensors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the glucose biosensors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The glucose biosensors market consists of sales of magnetic biosensors, thermometric biosensors, potentiometric, amperometric, and conductometric sensors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glucose Biosensors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses glucose biosensors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for glucose biosensors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glucose biosensors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.